SCHEMBL10044947

SCHEMBL10044947

COc1cc(C)c2c(c1)OCCO2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.40
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PKM P14618 4/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
MAPT P10636 3/20 0.37
TP53 P04637 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ATM Q13315 1/20 0.37
PKLR P30613 2/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12866043 0.85 ALDH1A1 (0.42) ALDH1A1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL18308449 0.79 ALDH1A1 (0.40) PLK1KDM4EALDH1A1L3MBTL1POLB
SCHEMBL30627575 0.79 PKM (0.43) PLK1KDM4EALDH1A1L3MBTL1POLB
SCHEMBL5570072 0.79 PLK1 (0.46) PLK1KDM4EALDH1A1L3MBTL1POLB
SCHEMBL5573739 0.78 KDM4E (0.43) PLK1KDM4EALDH1A1L3MBTL1POLB
SCHEMBL15199238 0.77 ALDH1A1 (0.37) ALDH1A1PKMNPC1RAB9AMAPT
SCHEMBL15180062 0.77 CA1 (0.47) PLK1KDM4EALDH1A1L3MBTL1POLB
SCHEMBL5573226 0.75 FFAR4 (0.40) PLK1KDM4EALDH1A1L3MBTL1POLB
SCHEMBL15988656 0.73 SMN1; SMN2 (0.41) PLK1KDM4EALDH1A1L3MBTL1POLB
SCHEMBL18308450 0.73 ALDH1A1 (0.50) PLK1KDM4EALDH1A1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-12-12 US disclosed
WO-2012052420-A1 METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES MERCK SERONO S.A. GENEVA (CH) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 PLK1 4022/4885KDM4E 1571/4885ALDH1A1 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.